Rich Pharmaceuticals (PK) Stock Price - RCHA

0.0001
0.00 (0.0%)
0.0001
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Rich Pharmaceuticals Inc (PK) RCHA OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.0001 0.00 0.00 0.00 0.0001 20:00:00
Bid Price Ask Price Spread Spread % News
0.0001 0.0001 0.00 0.0% - -
Stock Trades Traded Volume Average Volume 52 Week Range
1 2 2,895,449 0.000001 - 0.0003
Last Trade Time Type Quantity Stock Price Currency
14:57:34 2 $ 0.00005 USD

Rich Pharmaceuticals (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 207.19k 2.07B - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
21.00k $ - 0.00% - -

more financials information »

Rich Pharmaceuticals (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RCHA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00010.00010.00010.0001450,0000.000.0%
1 Month0.000050.00010.0000010.00009241,735,8830.00005100.0%
3 Months0.00020.00020.0000010.00009764,805,362-0.0001-50.0%
6 Months0.00020.00020.0000010.00010053,025,780-0.0001-50.0%
1 Year0.00010.00030.0000010.00018415,622,2790.000.0%
3 Years0.00010.00780.0000010.00077719,319,4070.000.0%
5 Years0.00050.00990.0000010.000437532,851,274-0.0004-80.0%

Rich Pharmaceuticals (PK) Description

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, TPA (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in this and possibly other indications is the result of the work of Prof. Richard Chang. He has conducted research on TPA for many years and has become an expert in the characteristics of this molecule. The findings form the scientific basis for the clinical use of TPA.


Your Recent History
USOTC
RCHA
Rich Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.